Theravance Inc. stands to make up to $545 million in a deal with GlaxoSmithKline plc to pool their respective long-acting beta 2 agonists to develop treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease. (BioWorld Today) Read More
